Bristol Myers Squibb Company's Inrebic has become the first new therapy in the EU in nearly a decade to get the green light for myelofibrosis (MF), joining Novartis AG and Incyte Corporation's Jakavi as an approved treatment for the bone marrow disorder.
BMS Buoyed By EU Approval Of Myelofibrosis Drug
Inrebic Came From Celgene Acquisition
There have been lots of twists and turns on the development path for Inrebic which is now the second JAK inhibitor to be approved in the EU for MF since the blockbuster Jakavi was cleared in 2012.
More from Anticancer
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
Miltenyi’s leadership calls for a streamlined regulatory framework as India gears to scale in cell and gene therapy. Executives from the German group also talked to Scrip about helping advance local capabilities, delivering point-of-care CAR- T cell therapy to hospitals and pricing dynamics.
More from Therapy Areas
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.